# The Supreme Court on Monday rejected appeals from pharmaceutical companies that object to negotiating Medicare drug prices with the federal government.

*biotech · news · 2026-05-18 · Newsmax*

## Key points

- The Supreme Court declined to hear pharma companies' appeals against Medicare drug price negotiations.
- Lower court rulings dismissing drug manufacturers' claims against the negotiation program remain in place.
- Medicare price negotiations currently cover 25 drugs, including Ozempic, Rybelsus, and Wegovy.
- Expanding to a third round, the program will soon cover 40 drugs with lower prices.
- Ending the Medicare drug negotiation program would require congressional action, as no end date is set.

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** United States

[Read the full story on Newsmax](https://www.newsmax.com/us/supreme-court-medicare-prescription-drug-price-negotiation/2026/05/18/id/1256623/)

---

Canonical: https://newsio.io/n/9b418f10-5709-4691-9da5-bbfe1abc75fe/the-supreme-court-on-monday-rejected-appeals-from-pharmaceutical-companies-that
Summarized by Newsio from Newsmax. https://newsio.io/how-it-works